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Abstract
Background: 2009 pandemic H1N1 (pH1N1) influenza posed an increased risk of severe illness among pregnant
women. Data on risk factors associated with death of pregnant women and neonates with pH1N1 infections are
limited outside of developed countries.
Methods: Retrospective observational study in 394 severe or critical pregnant women admitted to a hospital with
pH1N1 influenza from Sep. 1, 2009 to Dec. 31, 2009. rRT-PCR testing was used to confirm infection. In-hospital
mortality was the primary endpoint of this study. Univariable logistic analysis and multivariate logistic regression
analysis were used to investigate the potential factors on admission that might be associated with the maternal
and neonatal mortality.
Results: 394 pregnant women were included, 286 were infected with pH1N1 in the third trimester. 351 had
pneumonia, and 77 died. A PaO2/FiO2 ≤ 200 (odds ratio (OR), 27.16; 95% confidence interval (CI), 2.64-279.70) and
higher BMI (i.e. ≥ 30) on admission (OR, 1.26; 95% CI, 1.09 to 1.47) were independent risk factors for maternal
death. Of 211 deliveries, 146 neonates survived. Premature delivery (OR, 4.17; 95% CI, 1.19-14.56) was associated
neonatal mortality. Among 186 patients who received mechanical ventilation, 83 patients were treated with non-
invasive ventilation (NIV) and 38 were successful with NIV. The death rate was lower among patients who initially
received NIV than those who were initially intubated (24/83, 28.9% vs 43/87, 49.4%; p = 0.006). Septic shock was an
independent risk factor for failure of NIV.
Conclusions: Severe hypoxemia and higher BMI on admission were associated with adverse outcomes for
pregnant women. Preterm delivery was a risk factor for neonatal death among pregnant women with pH1N1
influenza infection. NIV may be useful in selected pregnant women without septic shock.
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Pregnant women are at an increased risk for contracting
influenza and its complications associated with influenza
[1]. Like previous epidemic and pandemic diseases, 2009
pandemic H1N1 (pH1N1) influenza posed an increased
risk of severe illness among pregnant women [2-9]. A
report from the first month of the pH1N1 outbreak noted
that the rate of hospitalization among pregnant women
was approximately four times the rate in the general popu-
lation in the USA [3]. As reported by the California
Department of Public Health (CDPH), a total of 10% of
the 1088 patients who were hospitalized or died from the
2009 pH1N1 influenza were pregnant [10]. According to
the Ministry of Health (MOH) of the People’s Republic of
China, pregnant women accounted for 13.7% of deaths
associated with 2009 pH1N1 influenza [11]. Pregnant
women with influenza appear to have an increased risk of
miscarriage, premature birth and stillbirth [2,12,13].
Reports from Victoria in Australia [14,15], New York [16],
and California [17], demonstrate that 2009 pH1N1 infec-
tion was associated with substantial maternal and fetal
morbidity and mortality. However, information is limited
concerning the risk factors for maternal and neonatal
death when pregnancy is complicated by severe or critical
illness related to 2009 pH1N1 influenza.
In this report, we described the characteristics of
pH1N1 influenza in pregnant women and the risk fac-
tors for maternal and neonatal death.
Methods
Study patients
All patients who were admitted to hospitals with con-
firmed 2009 pH1N1 influenza from Sep. 1 to Dec. 31,
2009 from 27 Chinese provinces were screened if they ful-
filled the diagnostic criteria for severe or critical cases. A
confirmed case was a person whose pH1N1 virus infection
was verified by real-time reverse-transcriptase polymerase
chain reaction (rRT-PCR) with or without the presentation
of other clinical symptoms. Patients were excluded if they
had been treated as outpatients or in emergency rooms or
duration of hospitalization < 24 h, or if they had incom-
plete records of clinical outcomes. Severe and critical
cases were defined according to the H1N1 2009 Clinical
guidelines (Third Edition, 2009) released by the MOH
(Additional file 1: Table S1). Our research retrospectively
collected the patient’s clinical information and did not
involve the patient’s personal information and samples, so
there was no informed consent.
Study design and data collection
The case report form included demographic information,
underlying conditions, gestational age, vaccination status,
treatment, intensive care unit (ICU) admission, complica-
tions, and maternal and neonatal outcomes. Body mass
index (BMI) was calculated using height and weight
recorded in the case report form, patients with BMI ≥ 30
were categorized as obesity. Indications for applying non-
invasive ventilation (NIV): pregnant women who com-
plained shortness of breath or blood gas analysis con-
firmed hypoxemia PaO2 to FiO2 < 300. One non-
pulmonary major organ dysfunction or unconsciousness
was contraindications for NIV. Indications to change
from NIV to invasive ventilation: A cautious trial of NIV
was attempted and response to NIV was monitored after
the first hour or two. If there was a deterioration of oxy-
genation, invasive ventilation was considered. Definition
of successful NIV: PaO2 to FiO2 improved and respira-
tory rate decreased during one or two hour NIV therapy.
The patients successfully weaned off NIV and survived.
Definition of failed NIV: During the one or two NIV trial,
a deterioration of oxygenation was observed and invasive
ventilation was needed. Data collection and analysis were
coordinated by the MOH. A standard data collection
form was used for each study site. Site investigators were
primarily infectious disease physicians closely involved in
taking care of such patients at their centers. The data
were entered in duplicate into a computerized database.
Patient confidentiality was maintained by recording only
patient date of birth and gender on the data collection
form. The research ethics board at Beijing Chao-Yang
H o s p i t a la n dT h eF i r s tA f f i l iated Hospital, School of
Medicine, Zhejiang University approved the study.
Analysis
We analyzed the reported demographic characteristics,
underlying conditions, symptoms, treatments, complica-
tions, clinical course and maternal and neonatal out-
comes. Means (standard deviations, SD) or medians
(interquartiles, IQR) were calculated as summaries of
continuous variables. For categorical variables, percen-
tages of patients in each category were calculated. We
compared clinical characteristics and clinical outcomes
by using an ANOVA test, chi-square test, or Fisher’s
exact test or Wilcoxon rank-sum test as necessary. The
primary outcome was in-hospital mortality. We per-
formed univariable logistic analysis to investigate the
potential factors on admission that might be associated
with the maternal mortality. Factors with statistical sig-
nificance (p <0 . 0 5 )i nt h eu n i v a r i a t ea n a l y s e sw e r e
included in the multivariate logistic regression analysis.
A p value of less than 0.05 was considered to indicate
statistical significance. All analysis was carried out using
SPSS for Windows (release 13.0).
Results
Clinical description of cohort
3570 severe or critical cases were screened and 394 cases
involved pregnant women (Figure 1). Demographic
Zhang et al. BMC Infectious Diseases 2012, 12:29
http://www.biomedcentral.com/1471-2334/12/29
Page 2 of 9characteristics, underlying conditions, symptoms, and lab
findings of the 394 pregnant women are illustrated in
Table 1. The median age was 25.0 years old (IQR 23.0 to
28.0) and 21 patients (5.6%) were more than 35 years old.
Of all available data, 35 patients (14.4%) had a BMI of
more than 30 and 10 patients (4.1%) had a BMI of more
than 35. The median gestational age was 32 weeks (IQR,
26 to 37), with 72.6% of patients in the third trimester. Ele-
ven patients (2.8%) had respiratory diseases and thirteen
(3.3%) had cardiovascular diseases. Other coexisting
Patients screened (n=3570)
With incomplete outcomes (n = 20)
Admitted in year 2010 (n = 32)
Not fulfilling the diagnosis of severe 
cases (n = 32)
Hospitalized severe and critical cases 
            ( n   =   3 4 8 6 )
    Pregnant  women  (n  =  394)
Non pregnant women (n = 3092)
Pregnant women who 
delivered
(n = 211)*
Pregnant women survived 
(n = 164)
Pregnant women died 
(n = 47)
Neonates survived 
(n = 145)
Neonates died 
(n = 63)
Discharged with ongoing 
pregnancy (n = 144)
Pregnant women lacking 
delivery data (n = 39)
Figure 1 Flow chart of patients enrolled and included in the analysis * Missing data for neonatal outcomes (n = 3).
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Page 3 of 9diseases were rare in this analysis. None of the patients
h a db e e ni m m u n i z e da g a i n s ts e a s o n a li n f l u e n z ao r2 0 0 9
pH1N1. The median APACHE II score was 7.0 (IQR, 4-
11). At the time of admission, 351 patients (90.0%) had
pneumonia with an abnormal chest radiography or chest
computed tomography. The most common symptoms
were cough (372; 94.7%) and dyspnoea (199; 50.6%). The
median PaO2/FiO2 on admission was 154.7 (IQR, 89.5-
320.5) (Table 1). Of the 394 hospitalized patients, 246
(63.7%) were admitted to an ICU at a median of 8 days
from onset of illness (IQR 5 to 14; Table 2).
Medication
378 (95.9%) patients received oseltamivir. The median
time from onset of illness to oseltamivir therapy was 5
days (IQR 3 to 7), among them only 52 patients (14.0%)
received oseltamivir within 48 h of onset of illness. 387
out of 394 patients received antibiotics. 244 received tra-
ditional Chinese medicine. Corticosteroid therapy was
administered to 242 patients (Table 2).
Maternal and neonatal outcomes
The most commonly reported complication in this study
was acute respiratory disease syndrome (ARDS) (151;
53.4%) (Table 2). 211 (59.4%) women delivered at a
median of 6 days (IQR 3 to 12) after pH1N1 symptom
onset. 122 out of 211 women delivered prematurely
(Additional file 2: Table S2). The most common delivery
method was cesarean delivery (172 patients, 82.7%)
(Table 2). Among 143 live-birth deliveries for which the
gestational age was known, 68 were premature (Addi-
tional file 2: Table S2). Among the 394 pregnant women
in the study, 77 died (Table 2), 56 out of the 77 patients
who died were in their third trimester. The main cause
of death was refractory hypoxemia (66 patients, 85.7%).
Of 5 patients with secondary infection, three patients
had Acinetobacter baumannii, one patient had Aspergil-
lus spp, and one patient had both Acinetobacter bau-
mannii and Aspergillus spp.
Mechanical ventilation
62.4% of women included in the study required inten-
sive care and 47.2% required mechanical ventilation. 83
Table 1 Demographic characteristics, underlying
conditions, symptoms and lab findings of 394 pregnant
patients*
Variables Value
Age, years
median years (IQR) 25 (23-28)
≤ 20 y (%) 23/375 (6.1)
20-35 y (%) 331/375 (88.3)
> 35 y (%) 21/375 (5.6)
Han Chinese (%) 371/393 (94.4)
Job
Farmer (%) 200/389 (51.4)
Unemployed (%) 84/389 (21.6)
Others (%)† 105/389 (27.0)
BMI, median (IQR) 26.0 (23.4-29.3)
≤ 25.0 (%) 99/243 (40.7)
25-30 (%) 99/243 (40.7)
30-35 (%) 35/243 (14.4)
> 35 (%) 10/243 (4.1)
Gestational age§
1
st trimester (0-14 week) (%) 20/394 (5.1)
2
nd trimester (15-27 week) (%) 88/394 (22.3)
3
rd trimester (≥ 28 week) (%) 286/394 (72.6)
Chronic pre-existing disease
Respiratory diseases** (%) 11/388 (2.8)
Cardiovascular diseases*** (%) 13/393 (3.3)
Diabetes mellitus (%) 4/394 (1.0)
Cancer or hematological diseases (%) 3/394 (0.8)
Immune suppressed (%) 1/390 (0.3)
Pneumonia (%) 351/390 (90.0)
Symptoms and Lab findings
T ≥ 38°C (%) 340/374 (90.9)
Cough (%) 372/393 (94.7)
Dyspnoea (%) 199/393 (50.6)
Hemoptysis (%) 55/392 (14.0)
Pleural effusion (%) 44/226 (19.5)
CNS symptom ※ (%) 48/392 (12.2)
WBC (×10
9/L) 7.4 ± 3.7
Platelet (×10
9/L) 169.0 ± 65.7
CK > 200 u/L (%) 77/306 (19.5)
CRP (mg/L) 42 (16-101)
ESR (mm/h) 35 (23-50)
PaO2/FiO2, median (IQR) 154.7 (89.5-320.5)
APACHE II scores, median (IQR) 7 (4-11)
IQR, interquartile range; BMI, body mass index; APACHE II, acute physiology
and chronic health evaluation II
* Data are presented as no./total no., if otherwise stated. Percentages are
based on women with complete information in the respective categories
Nineteen patients missed the detailed information. Percentages may not total
100 because of rounding
† Other job included student (in two patients), teacher (in twelve), babysitter
(in one), catering (in one), business service (in eleven), worker (in nine),
migrant laborer (in ten), herdsman (in one), professional staff member (in
seventeen), retired (in one), health care worker (in three), other detailed (in
thirty-seven)
§ The median gestational age was 32 weeks (IQR, 26-37 weeks)
** included asthma, COPD, active tuberculosis and other bronchial disease
***included coronary heart disease, chronic congestive heart failure, valvular
disease
※ CNS system symptoms: refers to one or more of the following symptoms:
insomnia, restlessness, hallucination, headache, dizziness and abnormal
behaviour
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NIV. Among 45 patients who failed with initial NIV, 38
of them were then administered invasive ventilation, and
24 of 38 these patients died. The death rate was lower
among patients who initially received NIV than those
were initially intubated (24/83, 28.9% vs 43/87, 49.4%; p
= 0.006).
Univariate analyses showed that patients who failed
NIV treatment had higher APACHE II scores (OR, 1.14;
95% CI, 1.02 to 1.27; p = 0.01), more CNS symptoms
(OR, 9.51; 95% CI, 1.15 to 79.03; p = 0.04), septic shock
(OR, 27.93; 95% CI, 3.34 to 33.47; p = 0.002), and a
higher incidence of acute liver damage (OR, 3.93; 95%
CI, 1.07 to 14.52; p = 0.04) compared with those who
succeeded with NIV therapy. Multivariable analyses sug-
gested that pregnant women with pH1N1 virus compli-
cated by septic shock (OR, 19.23; 95% CI, 1.97 to
187.13; p = 0.011) were less likely to be successfully
treated by NIV (Table 3).
Risk factor for maternal and neonatal death
62 out of 208 births resulted in neonatal death. 118 out of
208 births were premature. A multivariate analysis was
applied to investigate the factors associated with pregnant
outcomes. A PaO2/FiO2 ≤ 200 on admission (OR, 27.16;
95% CI 2.64 to 279.70, p < 0.001) and higher BMI (i.e. ≥
30) on admission (OR, 1.26; 95% CI 1.09 to 1.47, p =0 . 8 6 )
were independent risk factors for maternal death (Table
4). Premature delivery (OR, 4.17; 95% CI 1.19 to 14.56, p <
0.001) was associated with neonatal death (Table 5).
Discussion
The first case of 2009 pH1N1 virus infection in China
was documented on May 10, the virus has rapidly
spread throughout the mainland. A total of 126,000 con-
firmed cases were reported by Mar 31, 2010, including
7414 patients severe and 800 patients died. Among all
these severe cases, about 13.7% of patients were preg-
nant women [18].
In this large study of pregnant women who were hos-
pitalized with severe 2009 pH1N1 influenza, the clinical
characteristics were similar to those reported by others
[3,4,17,19]. 95.6% of patients were infected in the second
or third trimester. In our study, the most common
comorbidities were cardiovascular diseases (3.3%), dia-
betes mellitus (1.0%), respiratory diseases (2.8%), and
obesity (18.5%). In our study, the prevalence of underly-
ing diseases was much lower than reports from the Uni-
ted States (49.3%) [19], 56% in Australia [14], 34% in
California [17], 22.8% in Brazil [20], and 62% in France
[4]. In those studies, the main cause of underlying dis-
ease was asthma. A study compared asthma prevalence
of Chinese adolescents living in Canada and in China.
The authors found that for girls, the range of asthma
was 4.3% in Guangzhou to 9.8% in Canadian-born Chi-
nese adolescents. These results suggest that the lower
prevalence of pre-existing asthma in our samples reflects
prevalence of the disease in the Chinese population [21].
Table 2 Treatment, complications, outcomes among
pregnant women with confirmed 2009 pH1N1 influenza
and neonatal outcomes*
Variables Value
Treatment
Antibiotics (%) 387/394 (98.2)
Corticosteroids (%) 242/394 (61.4)
Mechanical ventilation** (%) 186/394 (47.2)
Non-invasive ventilation, successful(%) 38/170 (22.4)
Non-invasive ventilation, failed (%) 45/170 (26.5)
Initially intubated (%) 87/170 (51.1)
Oseltamivir (%) 378/394 (95.9)
Interval from onset to oseltamivir ≤ 48 h (%) 52/371 (14.0)
Interval from onset to oseltamivir > 48 h (%) 319/371 (86.0)
Traditional Chinese Medicine (%) 244/392 (62.2)
Complications
ARDS (%) 151/283 (53.4)
Septic shock (%) 51/254 (20.1)
Acute renal failure (%) 11/237 (4.6)
Acute liver damage‡ (%) 73/260 (28.1)
DIC (%) 8/234 (3.4)
Clinical course and Maternal Outcomes
ICU admission (%) 246/386 (63.7)
Length of ICU stay, median (IQR) 8 (5-14)
Time from onset to fever clearance, median (IQR) 7 (5-10)
Hospital stay for survivors, median (IQR) 11 (7-17)
In-hospital mortality (%) 77/394 (19.5)
Time from onset to death, median (IQR) 11 (7-17)
Delivery methods
Vaginal delivery (%) 31/208 (14.9)
Vacuum-assisted vaginal delivery (%) 2/208 (1.0)
Forceps-assisted vaginal delivery (%) 3/208 (1.4)
Cesarean delivery (%) 172/208 (82.7)
Neonatal outcomes
Survival 146/208 (70.2)
Stillbirth 36/208 (17.3)
Neonatal death 12/208 (4.8)
Spontaneous abortion 1/208 (0.5)
Therapeutic abortion 13/208 (6.3)
ARDS, acute respiratory distress syndrome; DIC, disseminated intravascular
coagulation; ICU, intensive care unit; IQR, interquartile range.
* Date are presented as no./total no. if otherwise stated. Percentages are
based on women with complete information in the respective categories.
** Sixteen patients missed the strategies of mechanical ventilation.
¶¶Acute renal failure: Serum Creatinine increased by 2-fold or GFR decreased
> 50%, or urine 0.5 ml/kg/h for at least 12 h.
‡ Acute liver damage: AST or ALT > 70 U/L, or Tbil > 2 mg/dL
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pregnant women in our study was 20%, similar to what
was reported in Canada, Mexico, and New Zealand
[22-25], but higher than in France (8% death in ICU-
hospitalized pregnancy women) [4]. Risk analysis
showed that a PaO2/FiO2 ≤ 200 and higher BMI (i.e. ≥
30) on admission were risk factors for maternal death.
Pregnancy and ARDS are associated with increased oxy-
gen consumption, which can result in hypoxemia in the
mothers and the neonates. We reported that a higher
BMI was associated with maternal mortality after adjust-
ing for baseline clinical factors. Observations of a high
prevalence of obesity in severe and fatal cases of 2009
pH1N1 infection have been reported in Chile, Canada,
the United Kingdom and Mexico [10,26,27]. As
observed in Australia, 42% of patients had a BMI of
more than 30 and 22% of patients more than 35, while
the corresponding proportions in the general Australian
pregnant population was 24% and 10% respectively [28].
However, our research retrospectively collected the
patient’s clinical information recorded in CRFs. Propor-
tion of obesity has been overestimated based on BMI in
the 3
rd trimester of pregnancy.
Data from previous pandemics and seasonal influenza
epidemics suggested that the risk of complications asso-
ciated with influenza might be higher in the second and
third trimester of pregnancy than in the first trimester
[2,3,17]. We also observed a higher proportion of mater-
nal death occurring in the second and third trimester.
During the 2009 H1N1 influenza pandemic, in the Uni-
ted States, the rate of premature birth (30.2%) was
higher than the rate of premature births (13%) reported
Table 3 Comparison between patients who succeeded with non-invasive ventilation and those who did not*
Characteristic Non-invasive ventilation
With successful
outcomes‡ (n = 38)
With failure
outcomes (n = 45)
P value ORuadj (95% CI) ORadj (95% CI)
Age (Mean ± SD, years) 26.1 ± 4.3 25.5 ± 4.3 0.61 0.97 (0.88-1.08)
BMI, median (IQR) 25.2 (24.4-28.8) 27.0 (24.5-30.4) 0.31 1.08 (0.93-1.25) 1.06 (0.72-1.56)
Gestational age, median (IQR) 32 (26-35) 32 (28-36) 0.96 0.99 (0.93-1.07) 0.97 (0.82-1.15)
Respiratory diseases (%) 2/37 (5.4) 1/44 (2.3) 0.48 0.42 (0.04-4.79)
Pneumonia (%) 37/38 (97.4) 43/45 (95.6) 0.65 1.76 (0.15-20.23)
Symptoms and Lab findings
T ≥ 38°C(%) 33/37 (89.2) 39/42 (92.9) 0.86 1.57 (0.33-7.56)
Dyspnoea (%) 24/38 (63.2) 31/44 (70.5) 0.43 0.68 (0.26-1.76)
Hemoptysis (%) 6/38 (15.8) 9/43 (20.9) 0.62 1.34 (0.42-4.23)
CNS symptom ※ (%) 1/38 (2.6) 9/44 (20.5) 0.04 9.51 (1.15-79.03) 1.48 (0.96-13.45)
WBC (×10
9/L), (Mean ± SD) 7.2 ± 3.6 7.6 ± 3.9 0.63 1.03 (0.91-1.16)
Hb (g/L) (Mean ± SD) 105.9 ± 15.6 99.0 ± 15.7 0.06 0.97 (0.94-1.02)
PLT (×10
9/L) (Mean ± SD) 155.5 ± 44.1 151.7 ± 56.7 0.75 1.00 (0.99-1.01)
ALT (U/L) (Mean ± SD) 43.3 ± 60.9 48.9 ± 61.2 0.69 1.002 (0.99-1.01)
CRP (mg/L) (Mean ± SD) 71.2 ± 52.9 90.8 ± 56.6 0.36 1.01 (0.99-1.02)
PaO2/FiO2
PaO2/FiO2 ≥ 300 (%) 7/24 (29.2) 3/33 (9.1) Referent
PaO2/FiO2 201 to 300 (%) 3/24 (12.5) 4/33 (12.1) 0.27 3.11 (0.41-23.93)
PaO2/FiO2 ≤ 200 (%) 14/24 (58.3) 26/33 (78.8) 0.06 4.33 (0.97-23.83)
APACHE II score, median (IQR) 7 (7-11) 10 (6-14) 0.01 1.14 (1.02-1.27) 1.20 (0.97-1.49)
Septic shock (%) 1/24 (4.2) 17/32 (53.1) 0.002 27.93 (3.34-33.47) 32.87 (1.91-566.52)
Acute liver damage **(%) 4/25 (16.0) 12/28 (42.9) 0.04 3.93 (1.07-14.52) 5.17 (0.47-56.37)
Pleural effusion (%) 11/35 (31.4) 12/40 (30.0) 0.89 1.07 (0.40-2.86)
ORuadj, unadjusted odds ratio; ORadj, Adjusted odds ratio; CI, confidence Interval; BMI, body mass index; IQR, interquartile range; APACHE II, acute physiology and
chronic health evaluation II; ICU, intensive care unit
* Date are presented as no./total no., if otherwise stated. Percentages are based on women with complete information in the respective categories
‡ included 38 patients survived after receiving NIV
¶ included 7 patients died of respiratory failure who received NIV, 38 patients who received NIV firstly, then changed to invasive ventilation
※ CNS system symptoms: refers to one or more of the following symptoms: insomnia, restlessness, hallucination, headache, dizziness and abnormal behaviour.
** Acute liver damage: AST or ALT > 70 U/L, or Tbil > 2 mg/dL.
Variables included in multivariate model: BMI, Gestational age, CNS symptom, APACHE II score, septic shock, acute liver damage
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Page 6 of 9Table 4 Univariate and multivariate regression analysis of the association of factors with death among pregnant
women with confirmed pH1N1 influenza*
Variables Patients who survived (n = 317) Patients who died (n = 77) P value ORuadj (95% CI) ORadj (95% CI)
Age, median years (IQR) 24.8 (22.9-28.3) 23.9 (21.7-28.3) 0.10 0.95 (0.90-1.01)
BMI, median (IQR) 25.99 (23.20-29.26) 27.37 (24.87-30.33) 0.02 1.10 (1.01-1.17) 1.26 (1.09-1.47)
Gestational age, median (IQR) 32 (26-37) 32 (26-38) 0.86 0.97 (0.97-1.03) 0.94 (0.86-1.03)
Comorbidity **(%) 25/317 (7.9) 6/77 (7.8) 0.97 0.98 (0.39-2.50)
Pneumonia (%) 275/311 (88.4) 75/77 (97.4) 0.03 4.91 (1.16-20.86) 0.68(0.02-2.39)
Symptoms and Lab findings
PaO2/FiO2, median (IQR)
PaO2/FiO2 ≥ 300 (%) 62/164 (37.8) 1/55 (1.8) Referent Referent
PaO2/FiO2 201 to 300 (%) 23/164 (14.0) 2/55 (3.6) 0.18 5.39 (0.47-62.33) 2.05 (0.09-46.80)
PaO2/FiO2 ≤ 200 (%) 79/164 (48.2) 52/55 (94.5) < 0.001 40.81 (5.49-303.51) 27.16 (2.64-279.70)
APACHE II score, median (IQR) 6 (3-10) 12 (8-16) < 0.001 1.13 (1.09-1.18) 1.07 (0.98-1.18)
Dyspnoea (%) 139/315 (44.1) 58/76 (76.3) < 0.001 4.08 (2.30-7.24) 1.81 (0.47-7.05)
Hemoptysis (%) 33/315 (10.5) 21/75 (28.0) < 0.001 3.32 (1.79-6.18) 1.64 (0.37-7.27)
CNS symptom (%) 29/314 (9.2) 19/76 (25.0) < 0.001 3.27 (1.71-6.24) 2.99 (0.63-14.14)
AST (u/L), median (IQR) 35 (23-65) 96.10 (44.50-159.5) < 0.001 1.007 (1.004-1.011) 1.00 (0.99-1.00)
OR, Odds Ratio; CI, confidence Interval; ORuadj, unadjusted odds ratio; ORadj, Adjusted odds ratio; BMI, body mass index; IQR, interquartile range; APACHE II, acute
physiology and chronic health evaluation II
* Data are presented as no./total no., if otherwise stated. Percentages are based on women with complete information in the respective categories
Variables included in univariate model: Age, BMI, Gestational age, comorbidity, pneumonia and symptoms and lab findings on admission associated with
mortality
Variables included in multivariate model: BMI, Gestational age, PaO2/FiO2 on admission, APACHE II score, dyspnoea, hemoptysis, CNS symptom, AST
** Comorbidity included Respiratory diseases (asthma, COPD, active tuberculosis and other bronchial disease), cardiovascular diseases (heart disease, chronic
congestive heart failure, valvular disease), diabetes mellitus, cancer or hematological diseases and Immune suppressed
Table 5 Univariate and multivariate analysis of the association of maternal characteristics with death among
neonates*
Variables Neonates who
survived (n = 145)
Neonates who
died (n = 63)
P value ORuadj (95% CI) ORadj (95% CI)
Maternal BMI, median (IQR) 27.5 (25.0-30.1) 25.6 (23.0-29.4) 0.06 0.91 (0.83-1.00) 1.05 (0.91-1.23)
Maternal Age, median years (IQR) 24.4 (20.9-27.9) 25.3 (22.5-28.6) 0.57 1.02 (0.96-1.08)
Gestational age
Non-premature delivery (≥ 37 weeks) 76/145 (52.4) 12/63 (19.0) Referent Referent
Preterm delivery (< 37 weeks) 69/145 (47.6) 51/63 (81.0) < 0.001 4.68 (2.31-9.51) 4.17 (1.19-14.56)
Comorbidities ** (%) 16/145 (11.0) 3 (4.8) 0.15 0.40 (0.11-1.44)
Symptoms and Lab findings
CNS symptom (%) 10/145 (6.9) 13/63 (20.6) 0.005 3.51 (1.45-8.51) 0.85 (0.08-9.47)
AST (u/L), median (IQR) 40 (26-76) 73 (36-139) 0.01 1.00 (1.00-1.01) 1.00 (0.99-1.01)
PaO2/FiO2 on admission
PaO2/FiO2 ≥ 300 (%) 61/161 (37.9) 2/58 (3.4) Referent Referent
PaO2/FiO2 201 to 300 (%) 22/161 (13.7) 3/58 (5.2) 0.13 4.16 (0.65-26.57) 3.59 (0.11-121.48)
PaO2/FiO2 ≤ 200 (%) 78/161 (48.4) 53/58 (91.4) < 0.001 20.72 (4.86-88.44) 12.33 (0.86-177.49)
APACHE II score, median (IQR) 8 (5-12) 10 (5-14) 0.17 1.04 (0.98-1.09) 0.99 (0.87-1.14)
OR, Odds Ratio; CI, confidence Interval; ORuadj, unadjusted odds ratio; ORadj, Adjusted odds ratio; BMI, body mass index; IQR, interquartile range; APACHE II, acute
physiology and chronic health evaluation II; ARDS, acute respiratory distress syndrome
* Date are presented as no./total no., if otherwise stated. Percentages are based on women with complete information in the respective categories
** Comorbidities included respiratory diseases (asthma, COPD, active tuberculosis and other bronchial disease), cardiovascular diseases (heart disease, chronic
congestive heart failure, valvular disease), diabetes mellitus, cancer or hematological diseases and Immune suppressed
Values in the multivariate analysis included maternal BMI, gestational age, CNS symptom, AST, APACHE II score and PaO2/FiO2 on admission
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Page 7 of 9in 2007 [29], consistent with data demonstrating a
higher rate of premature delivery during previous pan-
demics [2]. Among women in our study for whom data
on pregnancy outcomes was available, the rate of pre-
mature birth was 57.8%. In a multivariable analysis, pre-
term delivery contributed to fetal mortality. Delivery in
severe and critically infected women after 37 weeks’ of
gestation had improved neonatal outcomes compared to
similar patients who delivered before 37 weeks of
gestation.
Evidence on the useful role of NIV in pregnant
patients with ARDS secondary H1N1 viral infection was
lacking. Dr. Amit Banga [30] reported a 28-year-old
pregnant female with ARDS (PaO2/FiO2 155) due to
community-acquired severe pneumonia who successfully
treated with NIV. In 2009, Dr. Michel Djibre and colle-
gues [31] reported a 38-year-old pregnant woman at 31
weeks’ gestation with PaO2/FiO2 98 who was success-
fully treated with NIV. In our study, the success rate
among pregnant women with H1N1 infection for NIV
was 45.8%. A recent prospective multicenter survey also
found that when NIV was used as first-line therapy for
selected ALI/ARDS patients (those with 2 organ failures,
hemodynamic instability, or encephalopathy were
excluded), 54% avoided intubation and had excellent
outcomes [32].
A p a r tf r o mp r e v i o u sf i n d i n g st h a tm a j o ro r g a nd y s -
function and obtunded sensorium would obviously be
unsuitable candidates for NIV, we found that pregnant
women complicated by septic shock were less likely to
be successfully treated by NIV. Our data also support
that cautious selection of appropriate patients is impor-
tant for successful application of NIV. Patients should
be monitored closely for signs of NIV failure until stabi-
lized. If there are signs of NIV failure, patients should
be intubated promptly before a crisis develops.
Our investigation has several limitations. Firstly, we
only evaluated pregnant women admitted to a hospital
who fulfilled the diagnostic criteria of severe or critical
cases. Secondly, it was an observational study, and could
therefore only demonstrate associations and could not
infer cause. Thirdly, we lacked follow up visits for
maternal and neonatal outcomes. Lastly, despite the use
of a standardized data-collection form, not all informa-
tion was collected for all patients.
Conclusions
The clinical data reported herein is consistent with pre-
vious studies that demonstrate that pregnant women
with influenza are at an increased risk of serious illness
and death. Our novel findings included: 1) NIV was use-
ful for some selected pregnant women with pH1N1
virus infection complicated by respiratory failure, but
septic shock should be considered a contraindication; 2)
a PaO2/FiO2 ≤ 200 and higher BMI (i.e. ≥ 30) on admis-
sion were independent risk factors for maternal death;
3) Premature delivery was an independent risk factor for
neonatal death.
Additional material
Additional file 1: The diagnosis criteria for severe and critical cases.
Additional file 2: Maternal and neonatal outcomes by different
delivery methods in different trimesters. Data are presented as no.
(%)/total no.(%), if otherwise stated. Percentages are based on patients
with complete information in the respective categories. * Two patients
missed the detailed information in maternal outcomes. Neonatal
outcomes were unknown in four cases. ** One patient missed the
detailed information in maternal outcomes. Neonatal outcomes were
unknown in two cases.
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